Sanofi (NASDAQ:SNY) is one of the The Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) announced it has entered into a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a company that commercializes a hepatitis B vaccine and a differentiated shingles vaccine candidate.
Management noted that the acquisition aligns with the company’s strategy in expanding its presence in adult immunization through Dynavax candidates. Additionally, HEPLISAV-B is the only two-dose adult hepatitis B vaccine approved in the U.S. The drug is administered in two monthly doses for faster protection compared to competitors that administer three doses over six months.
The deal is valued at $15.50 per share in cash, adding approximately $2.2 billion in equity value. Additionally, the deal has already been unanimously approved by Dynavax’s board of directors and is expected to close in the first quarter of 2026. Management noted that this deal will not impact Sanofi’s (NASDAQ:SNY) financial guidance for 2025.
That said, Wall Street has a positive outlook on the stock, with analysts’ 12-month price target reflecting an upside of more than 26% from the current level. As recently as December 17, TD Cowen’s Steve Scala reiterated a Hold rating on the stock with a $57 price target.
Sanofi (NASDAQ:SNY) is a global healthcare company engaged in the research, development, manufacturing and marketing of therapeutic solutions in pharmaceuticals, vaccines and consumer healthcare.
While we recognize SNY’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.